Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro.

Biochemistry. 1999 Aug 31;38(35):11501-7. Unique Identifier : AIDSLINE MED/99400492
Hayakawa N; Nozawa K; Ogawa A; Kato N; Yoshida K; Akamatsu Ki; Tsuchiya M; Nagasaka A; Yoshida S; Department of Internal Medicine, Fujita Health University School; of Medicine, Toyoake, Aichi, Japan.

Abstract: The telomere hypothesis postulates stabilization of telomere length and telomerase activation as key events in cellular immortalization and carcinogeneses. Accordingly, telomerase has been suggested as a novel and highly selective target for design of antitumor drugs. Screening of a chemical library including 16 000 synthetic compounds yielded six that strongly inhibited telomerase activity in extracts of cultured human cells, including four isothiazolone derivatives and two unrelated compounds. The most potent inhibitor was 2-[3-(trifluoromethyl)phenyl]isothiazolin-3-one (TMPI), a concentration of 1.0 microM inhibited telomerase activity by 50% according to a telomere repeat amplification protocol (TRAP) assay. Analysis using partially purified telomerase from AH7974 rat hepatoma cells demonstrated noncompetitive inhibition with the telomere-repeat primer and mixed inhibition with the dNTPs; the inhibition constant was 2.5 microM. TMPI did not inhibit eukaryotic DNA polymerase alpha, beta, or human immunodeficiency virus reverse transcriptase (HIV RT). Thus, inhibition by TMPI was highly selective for telomerase. Inhibition by TMPI was quenched by 1 mM of dithiothreitol or glutathione, suggesting that TMPI inhibits telomerase by acting at a cysteine residue. TMPI inhibition of this enzyme may find application as an antineoplastic agent.

Keywords: JOURNAL ARTICLE Animal Antineoplastic Agents/ANTAGONISTS & INHIB/CHEMISTRY/*PHARMACOLOGY Dithiothreitol/PHARMACOLOGY DNA Polymerase beta/METABOLISM DNA Polymerase I/METABOLISM Enzyme Inhibitors/CHEMISTRY/*PHARMACOLOGY Glutathione/PHARMACOLOGY Human HIV-1 Reverse Transcriptase/METABOLISM HL-60 Cells Male Rats Rats, Inbred Strains Sulfhydryl Reagents/PHARMACOLOGY Telomerase/*ANTAGONISTS & INHIB/METABOLISM Thiazoles/ANTAGONISTS & INHIB/CHEMISTRY/*PHARMACOLOGY Tumor Cells, Cultured
991230
A99C1069

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .